Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against Cowpox virus Grishak infected in Vero cells measured after 4 days by colorimetric assay
Assay data:2 Active, 1 Activity ≤ 1 µM, 7 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Inhibition of p37 in Cowpox virus Grishak infected in African green monkey Vero cells assessed as reduction in viral reproduction incubated for 4 days by neutral red dye based colorimetric analysis
Assay data:6 Active, 3 Activity ≤ 1 µM, 12 Tested
Antiviral activity against Cowpox virus Grishak infected in African green monkey Vero cells assessed as reduction in cell survival incubated for 4 days by neutral red dye based colorimetric analysis
Assay data:3 Active, 5 Tested
SummaryCompounds, ActivePubMed Citation
Antiviral activity against Cowpox virus infected in HFF cells
Assay data:3 Tested
SummaryPubMed Citation
Antiviral activity against Cowpox virus infected in HFF after 3 days by neutral red dye-based plaque reduction assay
Assay data:4 Tested
Antiviral activity against Cowpox virus infected in african green monkey Vero 76 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
Antiviral activity against Cowpox virus infected in human HFF cells assessed as reduction of viral replication
Antiviral activity against Cowpox virus infected in HFF cells assessed as reduction of viral replication
Assay data:1 Tested
Antiviral activity against Cowpox virus infected in HFF assessed as reduction in virus induced cytopathic effect at 100 uM
Antiviral activity against Cowpox virus infected in human HFF cells after 3 days by Plaque reduction assay
Antiviral activity against Cowpox virus
Antiviral activity against Cowpox virus Brighton infected in HFF assessed as reduction of plaque formation after 3 days
Assay data:7 Active, 6 Activity ≤ 1 µM, 8 Tested
Antiviral activity against thymidine kinase positive Cowpox virus harboring deltacrmA lacZ infected in HFF after 48 hrs by beta-galactosidase assay
Assay data:3 Active, 1 Activity ≤ 1 µM, 4 Tested
Antiviral activity against thymidine kinase deficient Cowpox virus harboring TK:GFP lacZ infected in HFF after 48 hrs by beta-galactosidase assay
Assay data:2 Active, 1 Activity ≤ 1 µM, 4 Tested
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as uncured animal at 5 mg/kg, po bid for 5 days administered 3 days after infection relative to control
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as uncured animal at 15 mg/kg, po bid for 5 days administered 3 days after infection relative to control
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as uncured animal at 15 mg/kg, ip qd for 5 days administered 3 days after infection relative to control
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as day of death at 5 mg/kg, po bid for 5 days administered 2 days after infection
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as day of death at 15 mg/kg, po bid for 5 days administered 2 days after infection
Antiviral activity against Cowpox virus Brighton infected in BALB/c mouse assessed as uncured animal at 1.5 mg/kg, po bid for 5 days administered 2 days after infection relative to control
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on